Case Report

Zolpidem for Postanoxic Spasticity

Authors: Farhad F. Shadan, MD, PHD, J. Steven Poceta, MD, Lawrence E. Kline, DO, FACP

Abstract

A 28-year-old male sustained anoxic brain damage following aborted cardiac arrest, and subsequently developed severe muscular rigidity and spasticity involving all extremities. The spasticity was refractory to the standard regimens used for spastic hypertonia. Zolpidem dramatically inhibited muscular rigidity, spasticity, and dystonic posturing in a dose-dependent manner, resulting in a sustained improvement of his global performance over four years. The authors postulate a central mechanism of action by selective inhibition of GABAergic inhibitory neurons, and suggest a controlled clinical study to investigate the potential efficacy of zolpidem in relieving spasticity related to postanoxic brain injury.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Abbruzzese G. The medical management of spasticity. Eur J Neurol 2002;suppl 1:30 –34; discussion 53–61.
 
2. Elovic E. Principles of pharmaceutical management of spastic hypertonia. Phys Med Rehabil Clin N Am 2001;Nov;12:793–816.
 
3. Francisco GE, Kothari S, Huls C. GABA agonists and gabapentin for spastic hypertonia. Phys Med Rehabil Clin N Am 2001;Nov;12:875–888.
 
4. Daniele A, Albanese A, Gainotti G, et al. Zolpidem in Parkinson’s disease. Lancet 1997;349:1222–1223.
 
5. Langer SZ, Arbilla S, Scatton BV, et al. Receptors involved in the mechanism of action of zolpidem, in Sauvanet JP, Langer SZ, Morselli PL (eds):Imidazopyridines in sleep disorders: a novel experimental therapeutic approach. New York, Raven Press, 1988, pp 55–70.
 
6. Daniele A, Moro E, Bentivoglio AR. Zolpidem in progressive supranuclear palsy. New Engl J Med1999;341:543–544.